Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy

Schuetz, Florian; Diel, Ingo J.; Pueschel, Marit; Holst, T. von; Solomayer, Erich; Lange, Stefan; Sinn, Hans‐Peter; Bastert, G.; Sohn, Christof

doi:10.1016/j.ajog.2006.10.901

Cited by 40 publications

(35 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Use of HRT prior to diagnosis in this population was not significantly associated with either coffee consumption or risk for early events. Some studies have previously reported that HRT increases disease-free survival [40][41][42], while others have reported a higher mortality rate [42][43][44]. None of these potential confounders could explain the results of this study.…”

Section: Discussionmentioning

confidence: 46%

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status

Simonsson

Söderlind

Henningson

et al. 2013

Cancer Causes Control

View full text Add to dashboard Cite

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status.Simonsson, Maria; Söderlind, Viktoria; Henningson, Maria; Hjertberg, Maria; Rose, Carsten; Ingvar, Christian; Jernström, Helena General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Moderate to high coffee consumption was associated with significantly decreased risk for early events in tamoxifen-treated patients and modified hormone receptor status. If confirmed, new recommendations regarding coffee consumption during tamoxifen-treatment may be warranted.

show abstract

Section: Discussionmentioning

confidence: 46%

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status

Simonsson

Söderlind

Henningson

et al. 2013

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Breast cancer can spread to almost any area of the body. The most common organs are the lung, the bone, and the liver [19].…”

Section: Discussionmentioning

confidence: 99%

Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer

et al. 2009

View full text Add to dashboard Cite

The purpose of this study was to evaluate the efficacy of transarterial chemoembolization (TACE) using different drug combinations in the treatment of breast cancer liver metastases in terms of local tumor control and survival rate. A total of 208 patients (mean age 56.4 years, range 29-81) with unresectable hepatic metastases of breast cancer were repeatedly treated with TACE at 4-week intervals. In total, 1,068 chemoembolizations were performed (mean 5.1 sessions/patient, range 3-25). The chemotherapy protocol consisted of mitomycin-C only (8 mg/m(2); n = 76), mitomycin-C with gemcitabine (n = 111), and gemcitabine only (1,000 mg/m(2); n = 21). Embolization was performed with lipiodol and starch microspheres. Tumor response was evaluated by MRI according to RECIST criteria. Survival rates were calculated using Kaplan-Meier method. For all protocols, local tumor control was partial response 13% (27/208), stable disease 50.5% (105/208), and progressive disease 36.5% (76/208). The 1-, 2-, and 3-year survival rates after TACE were 69, 40, and 33%. Median and mean survival times from the start of TACE were 18.5 and 30.7 months. Treatment with mitomycin-C only showed median and mean survival times of 13.3 and 24 months, with gemcitabine only they were 11 and 22.3 months, and with a combination of mitomycin-C and gemcitabine 24.8 and 35.5 months. TACE is an optional therapy for treatment of liver metastases in breast cancer patients with better results from the combined chemotherapy protocol.

show abstract

“…Hormone therapy has been found to confer greater risk on invasive lobular, tubular, and mixed ductal-lobular histologic types (5-7)-types associated with better outcomes in some but not all studies-than for invasive ductal cancers. In addition, hormone therapy -associated tumors have been shown to be smaller (8)(9)(10)(11), hormone receptor positive (12)(13)(14), of lower grade (14)(15)(16)(17)(18), and to have fewer affected nodes (9,19) than tumors not associated with hormone therapy use. However, due to the strong correlation between histologic type and clinical characteristics, in particular estrogen receptor/ progesterone receptor (ER/PR) status (20)(21)(22)(23)(24), it is unclear which tumor subtypes are most strongly associated with hormone therapy use.…”

Section: Introductionmentioning

confidence: 99%

Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes

Slanger

Chang‐Claude

Obi

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Breast cancer is a heterogeneous disease with subtypes that may vary in their etiologies. Menopausal hormone therapy has been associated more strongly with lobular and tubular than ductal histologic types and with tumors that are smaller, hormone receptor -positive, and of lower grade. At the same time, correlations have been observed between histology and clinical characteristics. To identify those tumor subtypes most strongly associated with hormone therapy use, it is necessary to disentangle these interrelationships. Methods: Based on 3,464 postmenopausal breast cancer cases and 6,657 controls from the population-based Mammary carcinoma Risk factor Investigation study, we used polytomous logistic regression to evaluate associations between hormone therapy use and risk of invasive breast cancer subtypes. We assessed variations in risk for selected tumor characteristics among histologic and hormone receptor subtypes, both overall and for specific hormone therapy regimens.

show abstract

Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy

Cited by 40 publications

References 51 publications

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status

Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer

Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes

Contact Info

Product

Resources

About